Tengion, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNGNQ research report →
About the company
Tengion, Inc. was a biotechnology company focused on regenerative medicine, established in 2003 and headquartered in Winston-Salem, North Carolina. Its primary objective was the discovery, development, manufacturing, and commercialization of advanced cellular therapeutic products, often termed "neo-organs.
- CEO
- David I. Scheer
- IPO
- 2022
- Employees
- 25
- HQ
- Winston-Salem, US
Price Chart
- Market Cap
- $4.03K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 188.30%
- ROIC
- -159.36%
- Revenue
- $0 · 0.00%
- Net Income
- $-26,549,000 · -33.51%
- EPS
- $-6.60 · 21.24%
- Op Income
- $-16,597,000
- FCF YoY
- 11.53%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 79.90
- Avg Volume
- 159.04K
Get TickerSpark's AI analysis on TNGNQ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our TNGNQ coverage
Recent articles, reports, and earnings notes.
No research on TNGNQ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TNGNQ report →Similar companies
Peers in the same neighborhood.